Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date14 Feb 2020 |
/ Not yet recruitingPhase 4IIT A randomized, double-blind, parallel-group, multicenter clinical study to evaluate the efficacy and safety of Honghua Ruyi Wan in treatment of Pelvic inflammatory disease sequelae caused by chronic pelvic pain (qi stagnation and blood stasis syndrome)
100 Clinical Results associated with Gansu Foge Tibetan Medicine Co., Ltd.
0 Patents (Medical) associated with Gansu Foge Tibetan Medicine Co., Ltd.
100 Deals associated with Gansu Foge Tibetan Medicine Co., Ltd.
100 Translational Medicine associated with Gansu Foge Tibetan Medicine Co., Ltd.